AKBA
NSCAkebia Therapeutics Inc.
Healthcare•Biotechnology
Watchlists:
Last updated: Thursday 10th July 2025
3.99
+0.28 (7.55%)
Prev Close:3.71
Open:3.74
Bid:3.96
Ask:4.04
52 Week Range
1.074.08
Volume:4,806,453
Mkt Cap:974 M
51
MarketXLS Rank ®
Hold
Price Target
$4.59
+15.0%
Financials
Financial Statements
AKBA - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation And Amortization | 2 M | 2 M | 2 M | 2 M | -900000.0 | -600000.0 | -295000.0 | -96000.0 | ||
| Development Expense | 36 M | |||||||||
| Excise Taxes | 36 M | |||||||||
| Gain On Sale Of PPE | -524000.0 | |||||||||
| Gain On Sale Of Security | 800000.0 | 1 M | ||||||||
| General And Administrative Expense | 107 M | 100 M | 175 M | 174 M | 154 M | 149 M | -4 M | -3 M | 22 M | 18 M |
| Gross Profit Margin (profit Margin After CGS) | 133 M | 120 M | 207 M | 61 M | -2 M | 190 M | 200 M | 181 M | 2 M | |
| Impairment Of Capital Assets | 36 M | |||||||||
| Interest Expense Non Operating | 6 M | 16 M | 20 M | 9 M | ||||||
| Loss And Loss Adjustment Expected Incurred | 36 M | 32 M | ||||||||
| Misc Other Special Charges | -753000.0 | 887000.0 | 2 M | 2 M | 2 M | -794000.0 | 81000.0 | 204000.0 | -188000.0 | 287000.0 |
| Net Income (loss) | -69 M | -52 M | -94 M | -282 M | -385 M | -280 M | -144 M | -74 M | -136 M | -61 M |
| Net Income Common Stockholders | -69 M | -52 M | -94 M | -282 M | -385 M | -273 M | -144 M | -74 M | -136 M | -61 M |
| Net Income Continuous Operations | -69 M | -52 M | -94 M | -283 M | -383 M | -280 M | -144 M | -74 M | -136 M | -61 M |
| Net Non Operating Interest Income Expense | -18 M | -6 M | -16 M | -20 M | -9 M | 792000.0 | 6 M | 3 M | 901000.0 | 510000.0 |
| Net Operating Interest Income Expense | 510000.0 | |||||||||
| Normalized Income | 662 M | |||||||||
| Operating Income | -50 M | -46 M | -81 M | -265 M | -376 M | -286 M | -178 M | -77 M | -136 M | -62 M |
| Operating Income Before Depreciation (EBITDA) | -28 M | -8 M | -43 M | -228 M | -345 M | -248 M | -171 M | -72 M | -135 M | -60 M |
| Operating Expense | 147 M | 167 M | 272 M | 326 M | 376 M | 476 M | -378 M | -258 M | -138 M | -62 M |
| Other Gand A | 107 M | 100 M | 175 M | 174 M | 154 M | 149 M | -4 M | -3 M | 22 M | 18 M |
| Other Impairment Of Capital Assets | 32 M | |||||||||
| Other Operating Expenses | 5 M | 6 M | -3 M | -3 M | -3 M | -4 M | 67000.0 | -258 M | -138 M | -62 M |
| Other Write Off | 695 M | 100000.0 | 400000.0 | |||||||
| Rent And Landing Fees | -4 M | -3 M | 22 M | 18 M | ||||||
| Research Expense | 38 M | 63 M | 130 M | 148 M | 218 M | 323 M | 291 M | 231 M | 116 M | 43 M |
| Restructring And Mn A Income | 58000.0 | 181000.0 | 16 M | |||||||
| Salaries And Wages | 8 M | 9 M | -19 M | -12 M | -6 M | -5 M | ||||
| Selling And Marketing Expense | 87 M | 27 M | ||||||||
| Selling Expense | 87 M | 27 M | ||||||||
| Total Income Available For Interest Expense (EBIT) | -69 M | -52 M | -79 M | -265 M | -378 M | -286 M | -172 M | -74 M | -136 M | -61 M |
| Total Revenues | 160 M | 195 M | 292 M | 214 M | 295 M | 335 M | 208 M | 181 M | 2 M | |
| Total Expenses | 175 M | 205 M | 357 M | 479 M | 672 M | 621 M | -384 M | -258 M | -138 M | -62 M |
| Total Revenue | 160 M | 195 M | 292 M | 214 M | 295 M | 335 M | 208 M | 181 M | 2 M | |
| Amord | 59 M | 59 M | 59 M | 36 M | 55 M | 55 M | -2 M | |||
| Avgshs | 211 M | 187 M | 183 M | 166 M | 138 M | 118 M | 58 M | 44 M | 38 M | 26 M |
| Avgshsdt | 211 M | 187 M | 183 M | 166 M | 138 M | 118 M | 58 M | 50 M | 38 M | 27 M |
| Basiceps | -0.33 | -0.28 | -0.51 | -1.7 | -2.77 | -2.36 | 0.33 | |||
| Basicepscont | -0.33 | -0.28 | -0.51 | -1.7 | -2.77 | -2.36 | ||||
| Cor | 63 M | 38 M | 86 M | 151 M | 296 M | 145 M | -6 M | |||
| Depamor | 2 M | 2 M | 2 M | 2 M | -900000.0 | -600000.0 | -295000.0 | -96000.0 | ||
| Dileps | -0.33 | -0.28 | -0.51 | -1.7 | -2.77 | -2.36 | -2.47 | -1.69 | -3.6 | -2.29 |
| Dilepscont | -0.33 | -0.28 | -0.51 | -1.7 | ||||||
| Intinc | -18 M | -6 M | -16 M | -20 M | -9 M | 792000.0 | 6 M | 3 M | 901000.0 | 510000.0 |
| Netincdisc | -69 M | -52 M | -94 M | -282 M | -385 M | -280 M | -144 M | -74 M | -136 M | -61 M |
| Othincexp | 753000.0 | -363000.0 | -14 M | -2 M | 30 M | 794000.0 | -81000.0 | -204000.0 | 188000.0 | -287000.0 |
| Othspecchg | 36 M | |||||||||
| Pretaxinc | -69 M | -52 M | -94 M | -283 M | -383 M | -286 M | -172 M | -74 M | -136 M | -61 M |
| Resdev | 38 M | 63 M | 130 M | 148 M | 218 M | 323 M | 291 M | 231 M | 116 M | 43 M |
| Restruct | 58000.0 | 181000.0 | 16 M | |||||||
| Sga | 107 M | 100 M | 175 M | 174 M | 154 M | 149 M | 87 M | 27 M | 22 M | 18 M |
| Shsout | 236 M | 209 M | 184 M | 181 M | 154 M | 130 M | 117 M | 48 M | 39 M | 38 M |
| Specincchg | -36 M | -181000.0 | -16 M | -36 M | ||||||
| Taxprov | -7 M | -28 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.